Sunar Ulas, Rohrbach Daniel, Rigual Nestor, Tracy Erin, Keymel Ken, Cooper Michele T, Baumann Heinz, Henderson Barbara H
Department of Cell Stress Biology, Roswell Park Cancer Institute, Buffalo, NY, 14263, USA.
Opt Express. 2010 Jul 5;18(14):14969-78. doi: 10.1364/OE.18.014969.
We present initial results obtained during the course of a Phase I clinical trial of 2-1[hexyloxyethyl]-2-devinylpyropheophorbide-a (HPPH)-mediated photo-dynamic therapy (PDT) in a head and neck cancer patient. We quantified blood flow, oxygenation and HPPH drug photobleaching before and after therapeutic light treatment by utilizing fast, non-invasive diffuse optical methods. Our results showed that HPPH-PDT induced significant drug photobleaching, and reduction in blood flow and oxygenation suggesting significant vascular and cellular reaction. These changes were accompanied by cross-linking of the signal transducer and activator of transcription 3 (STAT3), a molecular measure for the oxidative photoreaction. These preliminary results suggest diffuse optical spectroscopies permit non-invasive monitoring of PDT in clinical settings of head and neck cancer patients.
我们展示了在一名头颈癌患者中进行的2-1[己氧基乙基]-2-去乙烯基焦脱镁叶绿酸-a（HPPH）介导的光动力疗法（PDT）I期临床试验过程中获得的初步结果。我们通过使用快速、非侵入性的漫射光学方法，在治疗性光疗前后对血流、氧合和HPPH药物光漂白进行了量化。我们的结果表明，HPPH-PDT诱导了显著的药物光漂白，并导致血流和氧合减少，提示存在显著的血管和细胞反应。这些变化伴随着信号转导和转录激活因子3（STAT3）的交联，这是氧化光反应的一种分子指标。这些初步结果表明，漫射光学光谱法可在头颈癌患者的临床环境中对PDT进行非侵入性监测。
